Michigan High Throughput Screening Center and NSF International Announce Partnership
News Aug 01, 2007
MHTSC is a not-for-profit, contract research laboratory that provides assay development and high throughput screening (HTS) services without licensing fees or royalties. Through the new partnership, pharmaceutical companies and biotechnology companies can now take advantage of HTS screening offered by MHTSC and high content screening offered by GLS – capabilities that are critical in drug development and research.
“As more and more drug companies outsource their research and testing, our goal is to provide solutions that will expedite the drug development process,” said Aline Lindbeck, Ph.D., general manager, Global Lifescience Solutions. “Our life-science organizations and state-of-the-art laboratories will position the State of Michigan as a leader in scientific research and high-tech screening services.”
Together, GLS and MHTSC will assist companies in identifying potential leads for drug discovery. GLS’ high content screening services provide preliminary toxicity data on drug candidates as well as additional information on the mechanisms by which drug candidates may elicit their cellular response.
Companies that will benefit from the new collaboration include public research institutions, government institutions, and biotechnology and pharmaceutical companies that conduct drug discovery work, as well as companies who do not have in-house high content or high throughput screening capabilities.
“Our mission at MHTSC is to provide access to state of the art screening technology and expertise,” said Rob Kilkuskie, Ph.D., senior director, Michigan High Throughput Screening Center. “Our collaboration with GLS allows us to expand the characterization of the compounds coming out of our screens. We believe this will greatly facilitate our clients’ drug discovery research.”
New service offerings under the partnership include:
• Prescreening services – help companies determine which targets should be fully screened
• Assay development – assay design and optimization
• Follow-up services – assist companies with follow-up screening and lead optimization
• High content screening – help companies examine multiple cellular targets and parameters in a large number of individually imaged cells and quantitatively assess the data
“The collaboration between GLS and MHTSC leverages the expertise and technology at each institution, and provides our clients an expanded array of screening services,” said Kathy Johnson, director of business development, MHTSC.
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
New Drug Compounds Help Prevent Hearing LossNews
Researchers from St. Jude Children's Research Hospital have discovered that inhibiting an enzyme called cyclin-dependent kinase 2 (CDK2) protects mice and rats from noise- or drug-induced hearing loss. The study suggests that CDK2 inhibitors prevent the death of inner ear cells, which has the potential to save the hearing of millions of people around the world.READ MORE
Empowering Women in Technology Key to Boosting UK EconomyNews
A new report launched at London Stock Exchange for International Women’s Day, reveals the critical role women play in driving economic growth across the UK, with detailed research on 1,279 women-led companies showing a total contribution of £25.9 billion in revenue to the UK economy.READ MORE